Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed papillary renal cell carcinoma (RCC)~  * Unresectable and/or metastatic disease~* Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension and is ≥ 10 mm by spiral CT scan~* No known CNS (central nervous system) disease~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG (Eastern Cooperative Oncology Group) performance status 0-1~* Life expectancy \> 6 months~* ANC (absolute neutrophil count) ≥ 1,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10.0 g/dL~* Total bilirubin ≤ 2.0 mg/dL~* AST (aspartate aminotransferase) and ALT (Alanine transaminase) \< 3 times normal~* Creatinine clearance \> 50 mg/mL~* Calcium \< 12 mg/dL (when corrected for level of serum albumin)~* No known HIV infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Inadequately controlled hypertension (defined as systolic blood pressure \[BP\] \> 150 mm Hg and/or diastolic BP \> 100 mm Hg on antihypertensive medications)~* Prior history of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association class II-IV congestive heart failure~* Myocardial infarction or unstable angina within the past 6 months~* Stroke or transient ischemic attack within the past 6 months~* Significant vascular disease (e.g., aortic aneurysm or aortic dissection)~* Symptomatic peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Significant traumatic injury within the past 28 days~* Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months~* Serious, non-healing wound, ulcer, or bone fracture~* Proteinuria at screening as demonstrated by either of the following:~  * Urine protein:creatinine (UPC) ratio ≥ 1.0 at screening~ * Urine dipstick for proteinuria ≥ 2+ OR 24-hour urine protein \> 1g~* Known hypersensitivity to any component of bevacizumab~PRIOR CONCURRENT THERAPY:~* No prior systemic treatment for metastatic papillary RCC~* At least 4 weeks since prior palliative radiotherapy of painful areas~* More than 28 days since prior major surgical procedure or open biopsy~* No concurrent major surgical procedure~* More than 7 days since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device~* Concurrent low-dose acetylsalicylic acid (≤ 325 mg/day) allowed in patients at high-risk for arterial thromboembolic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: EXPERIMENTAL): 15 mg/kg over 90 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).